Full Press Release Details
April 27, 2021 - MindMed (Nasdaq: MNMD, NEO: MMED, DE: MMQ), a leading psychedelic medicine biotech company, is pleased to announce the
start of trading on The Nasdaq Capital Market ("Nasdaq"). Trading will begin on Tuesday, April 27, 2021, under the symbol
"MNMD" on the Nasdaq.
MindMed will retain its listing on the Neo Exchange Inc. under the symbol "MMED". Once trading begins, the Company's subordinate
voting shares will convert from the OTCQB under the symbol "MMEDF" to the new symbol "MNMD".
will be a live bell ringing ceremony for MindMed on Thursday during the opening bell. Please use the following link to stream it live:
MindMed is a clinical-stage
psychedelic medicine biotech company that discovers, develops and deploys psychedelic inspired medicines and therapies to address addiction
and mental illness. The company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances
including Psilocybin, LSD, MDMA, DMT and an Ibogaine derivative, 18-MC. The MindMed executive team brings extensive biopharmaceutical
experience to MindMed's approach to developing the next generation of psychedelic-inspired medicines and therapies.
on the Canadian exchange NEO under the symbol MMED and in Germany under the symbol MMQ. MindMed will commence trading on the Nasdaq under
the symbol MNMD effective April 27, 2021; until then the Company will continue to trade in the United States under the symbol MMEDF on
in this news release related to the Company constitute "forward-looking information" within the meaning of applicable securities
laws and are prospective in nature. Forward-looking information is not based on historical facts, but rather on current expectations
and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially
from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use
of forward-looking words such as "will", "may", "should", "could", "intend", "estimate",
"plan", "anticipate", "expect", "believe", "potential" or "continue", or
the negative thereof or similar variations. Forward-looking information in this news release include statements related to the anticipated
benefits to the Company and its shareholders related to the listing on the Nasdaq and future plans and objectives of the Company. Although
the Company believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks
and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material
adverse effects on future results, performance or achievements of the Company. There are numerous risks and uncertainties that could
cause actual results and the Company's plans and objectives to differ materially from those expressed in the forward-looking information,
including history of negative cash flows; limited operating history; incurrence of future losses; availability of additional capital;
lack of product revenue; compliance with laws and regulations; difficulty associated with research and development; risks associated
with clinical trials or studies; heightened regulatory scrutiny; early stage product development; clinical trial risks; regulatory approval
processes; novelty of the psychedelic inspired medicines industry; as well as those risk factors discussed or referred to herein and
the risks described under the heading "Risk Factors" in the annual information form for the year ended December 31, 2020
and in other filings filed with the securities regulatory authorities in all provinces and territories of Canada and available under
the Company's profile on SEDAR at www.sedar.com and as described
in the information furnished to or filed with the U.S. Securities and Exchange Commission on EDGAR at www.sec.gov. Should one
or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect,
actual results and future events could differ materially from those anticipated in such information. Although the Company has attempted
to identify important risks, uncertainties and factors that could cause actual results to differ materially, there may be others that
cause results not to be as anticipated, estimated or intended. These and all subsequent written and oral forward-looking information
are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice.
Except as required by law, the Company does not intend and does not assume any obligation to update this forward-looking information.
Media Contact: mindmed@150bond.com